References
- Futterer JJ, Briganti A, De Visschere P, et al. Can clinically significant prostate cancer be detected with multiparametric magnetic resonance imaging? A systematic review of the literature. Eur Urol 2015;68:1045-1053 https://doi.org/10.1016/j.eururo.2015.01.013
- Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, version 2. Eur Urol 2016;69:16-40 https://doi.org/10.1016/j.eururo.2015.08.052
- Woo S, Suh CH, Kim SY, Cho JY, Kim SH, Moon MH. Head-to-head comparison between biparametric and multiparametric MRI for the diagnosis of prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol 2018;211:W226-W241 https://doi.org/10.2214/AJR.18.19880
- Purysko AS, Rosenkrantz AB, Barentsz JO, Weinreb JC, Macura KJ. PI-RADS version 2: a pictorial update. Radiographics 2016;36:1354-1372 https://doi.org/10.1148/rg.2016150234
- Iwazawa J, Mitani T, Sassa S, Ohue S. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging? Diagn Interv Radiol 2011;17:243-248
- Tamada T, Sone T, Higashi H, et al. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. AJR Am J Roentgenol 2011;197:664-670 https://doi.org/10.2214/AJR.10.5923
- Greer MD, Shih JH, Lay N, et al. Validation of the dominant sequence paradigm and role of dynamic contrast-enhanced imaging in PI-RADS version 2. Radiology 2017;285:859-869 https://doi.org/10.1148/radiol.2017161316
- Turco S, Lavini C, Heijmink S, Barentsz J, Wijkstra H, Mischi M. Evaluation of dispersion MRI for improved prostate cancer diagnosis in a multicenter study. AJR Am J Roentgenol 2018;211:W242-W251 https://doi.org/10.2214/AJR.17.19215
- Sanz-Requena R, Marti-Bonmati L, Perez-Martinez R, Garcia-Marti G. Dynamic contrast-enhanced casecontrol analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness. Eur J Radiol 2016;85:2119-2126 https://doi.org/10.1016/j.ejrad.2016.09.022
- Vos EK, Litjens GJ, Kobus T, et al. Assessment of prostate cancer aggressiveness using dynamic contrast-enhanced magnetic resonance imaging at 3 T. Eur Urol 2013;64:448-455 https://doi.org/10.1016/j.eururo.2013.05.045
- Ocak I, Bernardo M, Metzger G, et al. Dynamic contrastenhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR Am J Roentgenol 2007;189:849 https://doi.org/10.2214/AJR.06.1329
- Kim JK, Hong SS, Choi YJ, et al. Wash-in rate on the basis of dynamic contrast-enhanced MRI: usefulness for prostate cancer detection and localization. J Magn Reson Imaging 2005;22:639-646 https://doi.org/10.1002/jmri.20431
- Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology 2010;257:715-723 https://doi.org/10.1148/radiol.10100021
- Padhani AR, Gapinski CJ, Macvicar DA, et al. Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55:99-109 https://doi.org/10.1053/crad.1999.0327
- Riches SF, Payne GS, Morgan VA, et al. MRI in the detection of prostate cancer: combined apparent diffusion coefficient, metabolite ratio, and vascular parameters. AJR Am J Roentgenol 2009;193:1583-1591 https://doi.org/10.2214/AJR.09.2540
- Rosenkrantz AB, Kim S, Campbell N, Gaing B, Deng FM, Taneja SS. Transition zone prostate cancer: revisiting the role of multiparametric MRI at 3 T. AJR Am J Roentgenol 2015;204:W266-272 https://doi.org/10.2214/AJR.14.12955
- Schlemmer HP, Merkle J, Grobholz R, et al. Can preoperative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? Eur Radiol 2004;14:309-317 https://doi.org/10.1007/s00330-003-2025-2
- Franiel T, Hamm B, Hricak H. Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer. Eur Radiol 2011;21:616-626 https://doi.org/10.1007/s00330-010-2037-7
- Rosenkrantz AB, Ginocchio LA, Cornfeld D, et al. Interobserver reproducibility of the PI-RADS version 2 lexicon: a multicenter study of six experienced prostate radiologists. Radiology 2016;280:793-804 https://doi.org/10.1148/radiol.2016152542
- Hansford BG, Peng Y, Jiang Y, et al. Dynamic contrastenhanced MR imaging curve-type analysis: is it helpful in the differentiation of prostate cancer from healthy peripheral zone? Radiology 2015;275:448-457 https://doi.org/10.1148/radiol.14140847
- Feinstein AR, Cicchetti DV. High agreement but low kappa: I. The problems of two paradoxes. J Clin Epidemiol 1990;43:543-549 https://doi.org/10.1016/0895-4356(90)90158-L
- Cicchetti DV, Feinstein AR. High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol 1990;43:551-558 https://doi.org/10.1016/0895-4356(90)90159-M
- Oto A, Yang C, Kayhan A, et al. Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. AJR Am J Roentgenol 2011;197:1382-1390 https://doi.org/10.2214/AJR.11.6861
- Preziosi P, Orlacchio A, Di Giambattista G, et al. Enhancement patterns of prostate cancer in dynamic MRI. Eur Radiol 2003;13:925-930 https://doi.org/10.1007/s00330-002-1703-9
Cited by
- Optimization of Multi-Atlas Segmentation with Joint Label Fusion Algorithm for Automatic Segmentation in Prostate MR Imaging vol.24, pp.3, 2020, https://doi.org/10.13104/imri.2020.24.3.123